Register | Forgot password?
Switch to Arabic
Thursday, November 26 - 2009
Page navigation Browse related articles

The C Watcher Hepatitis C Program seeks to help people live a better life

  • United Arab Emirates: Tuesday, June 09 - 2009 at 13:44
  • PRESS RELEASE

The C Watcher campaign launched in the UAE is a program geared towards supporting people from different walks of life with a genuine hope to live better.

Article continues below
  • From the seminar.
    From the seminar.
The "Act Now, Live Better" campaign encourages people through a number of risk factors to assess whether they may have the hidden disease of Hepatitis C.

About 180m people worldwide are infected with the Hepatitis C disease which is a potentially serious condition that if left untreated, could kill over the course of 20 years.

The Hepatitis C virus transmitted through infected blood affects and damages the liver over a period of time and in some cases many of the infected persons may not be aware of the fact they are indeed carrying this disease until permanent damage has been done to the liver.

The good news for patients is that with the C WATCHER program, it is now possible for people to go through a free blood test to determine whether they are carrying this disease or not.

'Today we want to encourage people to assess whether they fall within one of the disease's risk factors and visit one of our partner labs to determine whether they carry the virus. In many cases now, Hepatitis C can be successfully treated.'


said Sherief Rizk, business unit director at Hoffmann-La Roche in the UAE.

Hoffmann-La Roche in cooperation with Emirates Gastroenterology Society has launched the 'C WATCHER program' on May 29, 2009. The C WATCHER is an integrated program aiming to facilitate the wellness of those affected by (Hepatitis C) through well designed activities of awareness, education and services.

The C Watcher activities include:


1. Awareness booklet distribution in medical institutions and main public area in UAE, includes all the information about hepatitis C as well as the main risk factors.
2. Distributing a free voucher along with (Are you at risk?) questionnaire for high risk population for free HCV anti-body test.
3. Radio advertisements highlighting the risk factors and the importance of testing.
4. Television interviews with health care professionals to highlight the mode of transmission and the importance of treatment.
5. Trained 'Patients Services Coordinators' to answer the public and patients queries through a toll free number 800 40 38.
6. A dedicated website (www.cwatcher.ae).
7. Healthcare professional's CME programs.
8. Fund raising activities.

The latest research has shown that clinical cure is in fact an achievable result for many patients with hepatitis C. The use of Roche's Pegasys, in combination with Copegus (ribavirin), has led to significant improvements in the number of patients achieving a cure (known as sustained virological response, or SVR, whereby the virus is still undetectable in patients' blood six months after they finish treatment).
Also consider reading:
Log in to request more information from Roche

Notes and media contacts

About chronic hepatitis C
The hepatitis C virus is transmitted primarily through blood or blood products. HCV chronically affects 180m people worldwide, which makes it over four times more prevalent than HIV. It is a leading cause of cirrhosis, liver cancer and liver failure, despite the fact that many patients can be cured.

About Roche
Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2008, Roche had over 80,000 employees worldwide and invested almost 9bn Swiss francs in R&D. The Group posted sales of 45.6bn Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan.

Disclaimer:

Articles in this section are primarily provided directly by the companies appearing or PR agencies which are solely responsible for the content. The companies concerned may use the above content on their respective web sites provided they link back to http://www.ameinfo.com

Any opinions, advice, statements, offers or other information expressed in this section of the AMEinfo.com Web site are those of the authors and do not necessarily reflect the views of AME Info FZ LLC / Emap Limited. AME Info FZ LLC / Emap Limited is not responsible or liable for the content, accuracy or reliability of any material, advice, opinion or statement in this section of the AMEinfo.com Web site.

For details about submitting your stories, please read the guide - all content published is subject to our terms and conditions